Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

被引:56
作者
McCall, AM
Shahied, L
Amoroso, AR
Horak, EM
Simmons, HH
Nielson, U
Adams, GP
Schier, R
Marks, JD
Weiner, LM
机构
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA
关键词
D O I
10.4049/jimmunol.166.10.6112
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We tested the hypothesis that bispecific Abs (Bsab) with increased binding affinity for tumor Ags augment retargeted antitumor cytotoxicity. We report that an increase in the affinity of Bsab for the HER2/neu Ag correlates with an increase in the ability of the Bsab to promote retargeted cytotoxicity against HER2/neu-positive cell lines. A series of anti-HER2/neu extracellular domain-directed single-chain Fv fragments (scFv), ranging in affinity for HER2/neu from 10(-7) to 10(-11) M, were fused to the phage display-derived NM3E2 human scFv. NM3E2 associates with the extracellular domain of human Fc gamma RIII (CD16). The resulting series of Bsab promoted cytotoxicity of SKOV3 human ovarian carcinoma cells overexpressing HER2/neu by human PBMC preparations containing CD16-positive NK cells. The affinity for HER2/neu clearly influenced the ability of the Bsab to promote cytotoxicity of Cr-51-labeled SKOV3 cells. Lysis was 6.5% with an anti-HER2/neu K-D = 1.7 x 10(-7) M, 14.5% with K-D = 5.7 x 10(-9) M, and 21.3% with K-D = 1.7 x 10(-10) M at 50:1 E:T ratios. These scFv-based Bsab did not cross-link receptors and induce leukocyte calcium mobilization in the absence of tumor cell engagement. Thus, these novel Bsab structures should not induce the dose-limiting cytokine release syndromes that have been observed in clinical trials with intact IgG Bsab. Additional manipulations in Bsab structure that improve selective tumor retention or facilitate the ability of Bsab to selectively cross-link tumor and effector cells at tumor sites should further improve the utility of this therapeutic strategy.
引用
收藏
页码:6112 / 6117
页数:6
相关论文
共 44 条
[1]  
Adams GP, 1998, CANCER RES, V58, P485
[2]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[3]  
BOLHUIS RLH, 1992, INT J CANCER, P78
[4]   Induction of multiple anti-c-erB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment [J].
Clark, JI ;
Alpaugh, RK ;
vonMehren, M ;
Schultz, J ;
Gralow, JR ;
Cheever, MA ;
Ring, DB ;
Weiner, LM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (05) :265-272
[5]   Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies [J].
Deo, YM ;
Graziano, RF ;
Repp, R ;
vandeWinkel, JGJ .
IMMUNOLOGY TODAY, 1997, 18 (03) :127-135
[6]  
DEPALAZZO IG, 1990, CANCER RES, V50, P7123
[7]   Characterization of human variable domain antibody fragments against the U1 RNA-associated A protein, selected from a synthetic and a patient-derived combinatorial V gene library [J].
deWildt, RMT ;
Finnern, R ;
Ouwehand, WH ;
Griffiths, AD ;
vanVenrooij, WJ ;
Hoet, RMA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (03) :629-639
[8]   CYTO-TOXICITY MEDIATED BY HUMAN FC-RECEPTORS FOR IGG [J].
FANGER, MW ;
SHEN, L ;
GRAZIANO, RF ;
GUYRE, PM .
IMMUNOLOGY TODAY, 1989, 10 (03) :92-99
[9]  
GEORGE AJT, 1994, J IMMUNOL, V152, P1802
[10]  
GRUBER M, 1994, J IMMUNOL, V152, P5368